Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron Has Strong Showing, But No REGEN-COV Sales Expected In First Half

Analysts Highlight Potential Growth Opportunities

Executive Summary

Dupixent sales grew by more than 50% as Eylea and REGEN-COV also drove sales growth, though the antiviral advantage will vanish due to the FDA restricting its use.

You may also be interested in...



Phase II Data May Be Good Sign For 8mg Aflibercept, But Will Payers Bite?

There are concerns that even with better efficacy and dosing versus Eylea and biosimilars, payers may impose step-edits on Regeneron’s new high-dose version.

Sanofi Unruffled By JAK Threat To Dupixent

CEO Paul Hudson tells Scrip that in an atopic dermatitis market that has a standard of care like Dupixent, "it's hard to justify the role of a JAK unless somebody has, frankly, failed everything else."

Roche Has Eylea In Its Sights After Farcimab Approval

Roche’s bispecific antibody, to be called Vabysmo, has got US approval for wet age-related macular degeneration and diabetic macular edema, markets where Bayer and Regeneron's Eylea is a huge seller. The Swiss company hopes that its less-frequent dosing advantage and a price that offers savings over time will make an impact on the market. 

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel